Nivolumab is an immunotherapeutic drug that targets PD-1 and inhibits the interaction between PD-1 and its ligand PD-L1, thereby restoring immune cell activity and strengthening the body’s defense against cancer. The gene discussed is CD274; the disease is cancer.